Boesenbergia pandurata as Anti-breast Cancer: Molecular Docking and ADMET Study

<em>Boesenbergia pandurata</em> or fingerroot is known to have various pharmacological activities, including anticancer. Extracts from these plants are known to inhibit the growth of cancer cells, including breast cancer. Anti-breast cancer activity is significantly influenced by the inhibition of two receptors: ER-α and HER2. However, it is unknown which metabolites of <em>B. pandurata</em> play the most crucial role in their anticancer activity. This study aimed to determine the metabolites of <em>B. pandurata</em> with the best potential as ER-α and HER2 inhibitors. The method used was molecular docking of several <em>B. pandurata</em> metabolites against ER-α and HER2 receptors, followed by an ADMET study of several metabolites with the best docking results. The docking results showed eight metabolites with the best docking results for the two receptors based on the docking score and ligand-receptor interactions. Of these eight compounds, compounds <strong>11</strong> ((2S)-7,8-dihydro-5-hydroxy-2-methyl-2-(4''-methyl-3''-pentenyl)-8-phenyl-2H,6H-benzo(1,2-b-5,4-b')dipyran-6-one) and <strong>34</strong> (geranyl-2,4-dihydroxy-6-phenethylbenzoate) showed the potential to inhibit both receptors. Both ADMET profiles also show mixed results but still allow for further development. In conclusion, the metabolites of <em>B. pandurata</em> especially compounds <strong>11</strong> and <strong>34</strong>, can be developed as anti-breast cancer through the inhibition of ER-α and HER2.